No Data
First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ
Express News | FDA: Approval of Cobenfy Was Granted to Bristol-Myers Squibb Company
Express News | FDA: Approved Cobenfy (Xanomeline and Trospium Chloride) Capsules for Oral Use for the Treatment of Schizophrenia in Adults
Express News | FDA: Approves Drug With New Mechanism of Action for Treatment of Schizophrenia
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants With Lowest Short Interest in 2024